CENTESSA
Live / Applied — Second extension granted (statement of use) (as of 27 Jan 2026)
What this means for you
Not registered yet, but its 09 Aug 2021 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90872691
- Mark type
- Stylized text
- Filed
- 09 Aug 2021
- Published for opposition
- 17 Dec 2024
- Attorney of record
- Brandon P. Leahy
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical products, preparations, and medicines for the treatment or prevention of hemophilia, tumors, hypertension, narcolepsy, inflammatory diseases or disorders, fibrotic diseases or disorders, autoimmune diseases or disorders, respiratory diseases or disorders, cardiovascular diseases or disorders, central nervous system diseases or disorders, immune system diseases or disorders, cancer, intractable diseases of liver, lung, and heart, and endocrinology diseases or disorders
- Class 010 — Medical apparatus: Medical devices, namely, drug delivery devices and devices for delivering nasal spray treatments
- Class 042 — Scientific and technological services: Scientific and technological services and research in the medical and pharmaceutical field, namely, pharmaceutical product development; pharmaceutical research services; Pharmaceutical drug development services; Research and development in the pharmaceutical and biotechnology fields; Pharmaceutical research and development; Medical laboratories; Scientific and technological services and research and design relating thereto in the field of drug discovery; development of computer hardware and software
- Class 044 — Medical, beauty and agricultural services: Medical services; providing medical information and pharmaceutical information services, namely, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical and pharmaceutical consultation and counseling services; treatments for orphan diseases of the kidney, including ADPKD (Autosomal dominant polycystic kidney disease); medical services, namely, providing medical therapies for hemophilia; medical services, namely, administration of pharmaceutical treatments for pulmonary arterial hypertension, oncological and autoimmune diseases; medical services, namely, providing medical treatments for narcolepsy; medical services, namely, providing medical treatments for skin disorders
Owner
- Centessa Pharmaceuticals plc, Cheshire, GB
- Centessa Pharmaceuticals plc, Cheshire, GB
Prosecution history
- 28 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Jan 2026 — SOU EXTENSION 2 GRANTED
- 27 Jan 2026 — SOU EXTENSION 2 FILED
- 27 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 12 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Jul 2025 — SOU EXTENSION 1 GRANTED
- 11 Jul 2025 — SOU EXTENSION 1 FILED
- 11 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 11 Feb 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 17 Dec 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Dec 2024 — PUBLISHED FOR OPPOSITION
- 11 Dec 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 21 Nov 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 03 Oct 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 02 Oct 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE